AbbVie vs Alnylam Pharmaceuticals
AbbVie (ABBV) and Alnylam Pharmaceuticals (ALNY) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $506B
- Last close
- $286.20
- 12 months
- +24.7%
- Market value
- $19.3B
- Last close
- $143.82
- 12 months
- −67.7%
At a glance
- The biggest part of Alnylam Pharmaceuticals's revenue is AMVUTTRA, 62% of the total in its last annual report.
- By market value, AbbVie ($505.9B) is about 26 times Alnylam Pharmaceuticals ($19.3B).
- Over the last 12 months AbbVie's share price moved +24.7% and Alnylam Pharmaceuticals's −67.7%; against the S&P 500 that is +19.0 points and −73.5 points.
- In their last fiscal years AbbVie kept 6.9% of revenue as net income and Alnylam Pharmaceuticals 8.4%.
- In the last 90 days insiders reported 0 open-market purchases at AbbVie and 2 at Alnylam Pharmaceuticals; members of Congress disclosed 1 trade in AbbVie and 0 in Alnylam Pharmaceuticals.
- Next results: AbbVie Feb 2, 2027, Alnylam Pharmaceuticals Feb 10, 2027.
How each one makes money: AbbVie revenue · Alnylam Pharmaceuticals revenue
Share prices on one chart
AbbVie and Alnylam Pharmaceuticals, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| AbbVie ABBVNYSE · Pharmaceuticals | Alnylam Pharmaceuticals ALNYNASDAQ · Pharmaceutical Preparations | |
|---|---|---|
| Size and profitability | ||
| Market value | $506B | $19.3B |
| Revenue, last fiscal year | $61.2B | $3.71B |
| Net income, last fiscal year | $4.23B | $314M |
| Net marginNet income as a share of revenue | 6.9% | 8.4% |
| Free cash flow | $17.8B | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
AbbVie against
Common questions
How is AbbVie different from Alnylam Pharmaceuticals?
AbbVie (ABBV) is in Pharmaceuticals on NYSE, with $61.2B of revenue in its last fiscal year and a net margin of 6.9%. Alnylam Pharmaceuticals (ALNY) is in Pharmaceutical Preparations on NASDAQ, with $3.71B of revenue in its last fiscal year and a net margin of 8.4%. The biggest part of Alnylam Pharmaceuticals's revenue is AMVUTTRA, 62% of the total in its last annual report. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do AbbVie and Alnylam Pharmaceuticals compare in size?
AbbVie has the larger market value: AbbVie $506B and Alnylam Pharmaceuticals $19.3B, at the last close.
Whose share price rose more over the last 12 months, ABBV or ALNY?
Over the last 12 months AbbVie moved +24.7% and Alnylam Pharmaceuticals −67.7%. Past price moves say nothing about the future.
Which has had more insider buying, AbbVie or Alnylam Pharmaceuticals?
Since 2006, Alnylam Pharmaceuticals insiders reported 37 open-market purchases against 25 for AbbVie. These are counts of what was filed, not a view on either stock.
Do members of Congress trade ABBV or ALNY?
In the last 12 months, members of Congress disclosed 9 trades in AbbVie (ABBV) and 0 in Alnylam Pharmaceuticals (ALNY).
When did insiders last buy ABBV and ALNY?
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
AbbVie pageAlnylam Pharmaceuticals pageRare insider trades this weekAll comparisons
https://oqro.io/compare/abbv-vs-alny







